In Brief: CDRH personal conferencing
This article was originally published in The Gray Sheet
Executive Summary
CDRH personal conferencing: FDA's device center seeks industry participants to take part in evaluating the agency's electronic personal conferencing system ("The Gray Sheet" April 17, p. 4). Currently under trial within the center, the system "enables two people, at remote locations, to see and hear each other while reviewing and/or editing the same document shown on both computer screens" and allows "for the transmission of voice, video, and data displayed in a Windows application over a single communication link," FDA explains. In the next phase of testing, the agency plans to use the system in conjunction with device sponsors to "interactively and simultaneously discuss and modify documents which relate to new device applications," such as investigational device exemption protocols, deficiency letters, data summaries or labeling. For further information, contact Office of Information Systems Director Neil Goldstein at 301/594-4585...You may also be interested in...
Abbott Readying Vildagliptin ER In India Amid Price Competition
AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: